Your session is about to expire
← Back to Search
MT-1186 for Lou Gehrig's Disease
Study Summary
This trial will compare the efficacy of two dosing regimens of oral edaravone in subjects with ALS. The primary endpoint is the change in ALSFRS-R score from baseline up to Week 48.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 185 Patients • NCT04165824Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this research project have an age restriction of seventy-five years or younger?
"As specified by the eligibility requirements, the minimum age for trial participation is 18 years old and the maximum age is 75 years old."
Does this experiment have numerous test locations in North America?
"This trial is currently being conducted out of 44 different hospitals, with the UF Health Cancer Center in Gainesville, Florida, CHU de Quebec-Hopital-Enfant-Jesus in Quebec City, Quebec, and West virginia University School of Medicine (WVUSoM) - Movement Disorder Clinic in Morgantown, West Virginia being some of the more notable ones."
What other medical research has been published on MT-1186?
"Currently, 9 clinical trials are underway to study MT-1186. Of these 9 research projects, 3 are in Phase 3. Although the primary locations for these trials are in Shanghai, there are a total of 169 research sites running these trials."
When will MT-1186 be cleared for use in the United States?
"Our company, Power, rates the safety of MT-1186 as a 3. This is based on the fact that MT-1186 is in Phase 3 clinical trials. Thus, there is some evidence of efficacy as well as multiple rounds of data supporting safety."
Are there current vacancies for this research project?
"That is correct. The clinical trial in question, which was first announced on November 13th 2020, is still recruiting patients. In total, they are looking for 380 patients to be spread out across 44 different locations."
Share this study with friends
Copy Link
Messenger